Literature DB >> 3572614

Cytoplasmic reactivity with the monoclonal antibody HMFG1 as a marker of cervical glandular atypia.

L J Brown, N R Griffin, M Wells.   

Abstract

Cervical adenocarcinomas show cytoplasmic reactivity with the monoclonal antibody HMFG1 in contrast to the luminal border (cuticular) staining seen in normal endocervical glands and microglandular hyperplasia. HMFG1 was applied to 15 cases of cervical glandular atypia: thirteen showed cytoplasmic reactivity similar to that seen in overt endocervical neoplasia. This pattern of reactivity seems to be a useful marker of cervical glandular atypia and further supports its suggested place in the development of adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3572614     DOI: 10.1002/path.1711510308

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  4 in total

1.  Nucleolar organiser regions in adenocarcinoma in situ and invasive adenocarcinoma of the cervix.

Authors:  J F Darne; S V Polacarz; E Sheridan; D Anderson; R Ginsberg; F Sharp
Journal:  J Clin Pathol       Date:  1990-08       Impact factor: 3.411

2.  Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas.

Authors:  S Y Liao; C Brewer; J Závada; J Pastorek; S Pastorekova; A Manetta; M L Berman; P J DiSaia; E J Stanbridge
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

3.  Endocervical carcinoma and precursor lesions: c-myc expression and the demonstration of field changes.

Authors:  S V Polacarz; J Darne; E G Sheridan; R Ginsberg; F Sharp
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

4.  Expression of epithelial membrane and 3-fucosyl-N-acetyllactosamine antigens in cervix uteri with particular reference to adenocarcinoma in situ.

Authors:  T P Rollason; P Byrne; A Williams; G Brown
Journal:  J Clin Pathol       Date:  1988-05       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.